Axovant's nelotanserin heading to Phase III

Axovant Sciences Ltd. (NYSE:AXON) said it plans to begin a Phase III trial in 2H17 of nelotanserin based on interim data from 11 patients in a Phase II study to treat Lewy body dementia. The candidate met a primary endpoint assessing extrapyramidal signs, but missed secondary endpoints evaluating visual hallucinations.

The company intends to expand the Phase II study and complete it by mid-year. Spokesperson Jonathon Neely told BioCentury the study's original target enrollment was 20 patients, but he declined to give a new target...